Study Purpose:
MND-SMART is investigating whether selected drugs can slow down the progression of motor neurone disease (MND) and improve survival.The study is 'multi-arm' meaning more than one treatment will be tested at the same time. The trial started with 3 arms; drug 1, drug 2 and placebo (dummy drug). The trial currently has 4 arms; drug 1, drug 2, drug 3, and placebo. This allows the evaluation of each drug versus placebo. Participants will be randomly allocated to either drug 1, drug 2, drug 3, or placebo. Medicines being tested are already approved for use in other conditions.
MND-SMART has an 'adaptive' design. This means medicines being studied can change according to emerging results. Treatments shown to be ineffective can be dropped and new drugs can be added over the duration of the study. This will allow many treatments, over time, to be efficiently and definitively evaluated.
The medicines being tested have been selected following a rigorous process involving a systematic, unbiased, and comprehensive review of past clinical trials data, as well as information from pre-clinical research (studies in laboratories), for MND and other related neurodegenerative disorders. Drugs have been ranked for inclusion in MND-SMART by a group of independent MND experts according to set criteria. These include consideration of how the drugs work, their safety profiles, and the quality of previous studies.
New drugs will be selected for investigation in MND-SMART based on continuous review of constantly updated scientific evidence as well as findings from state-of-the-art human stem cell based drug discovery platforms. These can be added by substantial amendment to the protocol.
Study Status:
Recruiting
Disease:
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Study Type:
Interventional
Type of Intervention:
Drug
Intervention Name:
Memantine Hydrochloride Oral Solution, Trazodone Hydrochloride oral solution, Placebo oral solution, Amantadine Hydrochloride Oral Solution
Placebo:
Yes
Phase:
Phase 2/Phase 3
Study Chair(s)/Principal Investigator(s):
Professor Chandran, University of Edinburgh
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Professor Chandran / email hidden; JavaScript is required / 0131 465 9612
Full Study Summary:
Study Sponsor:
University of Edinburgh
Estimated Enrollment:
800
Estimated Study Start Date:
02 / 27 / 2020
Estimated Study Completion Date:
12 / 01 / 2026
Posting Last Modified Date:
04 / 26 / 2023
Date Study Added to neals.org:
03 / 10 / 2020
Minimum Age:
18 Years
Maximum Age:
N/A
Inclusion Criteria:- Confirmed diagnosis of MND (including the following subtypes: ALS by El Escorial Criteria (possible, probable, and definite), Primary Lateral Sclerosis, and Progressive Muscular Atrophy)
- Over 18
- Women of childbearing potential according to Clinical Trials Facilitation and Coordination Group (CTFG) guidelines must have a negative pregnancy test within 7 days prior to, or at, the baseline visit
- Women of childbearing potential and fertile men must be using an appropriate method of contraception to avoid any unlikely teratogenic effects of the selected drugs from time of consent, to 4 weeks after treatment inclusive
- Willing and able to comply with the trial protocol and ability to understand and complete questionnaires
- Written informed consent (this can be signed by a proxy in the case of limb dysfunction)
Exclusion Criteria:
- Patients diagnosed with Frontotemporal Dementia (FTD-MND) or any other significant psychiatric disorder that prevents informed consent being given.
- Patients in the manic phase of bipolar disorder.
- Alcoholism (self-reported)
- Active suicide ideation assessed using the Columbia-Suicide Severity Rating Scale
- On concurrent investigational medication (including biological therapy)
- Known hypersensitivity, including hereditary fructose intolerance, or adverse reaction to the active substances and their excipients (SPCs section 6.1) or any past medical history contraindicating use of any of the IMPs
- Pregnancy or breast-feeding females
- If ALT, ALP, bilirubin or GGT >3 times the upper limit of normal.
- If creatinine clearance (creatinine clearance or eGFR) <35 ml/min.
- If TSH <0.2mU/l (if possible to test free T4, then Serum free T4 >25pmol/l)
- corrected QT interval on 12 lead ECG >500 ms
- Active Epilepsy
- History of proven peptic ulcer confirmed on endoscopy
- Patient's diagnosed with ventricular arrhythmias, significant heart block (at the investigator's discretion) or in the immediate recovery period after myocardial infarction (< 6 weeks).
- Already taking any of the IMPs in this protocol
- Patient's contraindicated to any of the IMPs according to SPC section 4.3
- Taking a medication that interacts with the active substances and their excipients according to the SPCs, including but not limited to; Dextromethorphan, Amantadine; Ketamine, Monoamineoxidase inhibitors ((MAOIs), Rasagiline, Selegiline, Safinamide, Tranylcypromine, Phenelzine, Isocarboxazid, Moclobemide).
- Patients who the PI considers will not be able to comply with the study protocol.
Southern Health and Social Care Trust, Craigavon Area Hospital | Recruiting
Raeburn Forbes
Portadown, County Armagh
BT63 5QQ
United Kingdom
NHS Highland Clinical Research Facility, Raigmore Hospital | Recruiting
Javier Carod Artal
Inverness
United Kingdom
Clinical Research Facility Salford Royal NHS Foundation Trust | Recruiting
Hisham Hamdalla
Salford
United Kingdom
University Hospitals of Dorset NHS Trust | Recruiting
Principal Investigator : Charles Hillier
Poole
United Kingdom
Norfolk and Norwich University Hospitals NHS Foundation Trust | Recruiting
Godwin Mamutse
Norwich NR4 7UY
United Kingdom
Newcastle upon Tyne Hospitals NHS Foundation Trust | Recruiting
Tim Williams
Newcastle Upon Tyne NE7 7DN
United Kingdom
St George's University Hospitals NHS Foundation Trust | Recruiting
Pablo Garcia Reitboeck
London SW17 0QT
United Kingdom
Royal London Hospital | Recruiting
Aleks Radunovic
London E1 1FR
United Kingdom
East Suffolk and North Essex NHS Foundation Trust | Recruiting
Clare Galton
Ipswich CO4 5JL
United Kingdom
Queen Elizabeth University Hospital Clinical Research Facility | Recruiting
George Gorrie
Glasgow
United Kingdom
Aberdeen Royal Infirmary | Recruiting
Callum Duncan
Aberdeen
United Kingdom
Royal Devon and Exeter Hospital | Recruiting
Timothy Harrower
Exeter
United Kingdom
Anne Rowling Regenerative Neurology Clinic | Recruiting
Judith Newton / 0131 465 9517 / email hidden; JavaScript is required
Edinburgh EH16 4SB
United Kingdom
Clinical Research Centre , Ninewells Hospital | Recruiting
Ian Morrison
Dundee
United Kingdom
Cardiff and Vale University Local Health Board | Recruiting
Ken Dawson
Cardiff CF14 4XW
United Kingdom
Cambridge University Hospitals NHS Foundation Trust | Recruiting
Rhys Roberts
Cambridge CB2 0QQ
United Kingdom
West Suffolk NHS Foundation Trust | Recruiting
Francesca Crawley
Bury Saint Edmunds IP33 2QZ
United Kingdom
University Hospitals of Birmingham NHS Foundation Trust | Recruiting
Venkatamaran Srinivasan
Birmingham B15 2TH
United Kingdom
Clinical Research Facility University Hospital Southampton | Recruiting
Ashwin Pinto
Southampton
United Kingdom